Falcinelli, Marta http://orcid.org/0000-0001-6496-6953
Dell’Omo, Giulia
Grassi, Elena http://orcid.org/0000-0003-1066-927X
Mariella, Elisa
Leto, Simonetta Maria http://orcid.org/0000-0001-7580-6584
Scardellato, Sharon
Lorenzato, Annalisa
Arena, Sabrina http://orcid.org/0000-0002-1318-2494
Bertotti, Andrea
Trusolino, Livio http://orcid.org/0000-0002-6379-3365
Bardelli, Alberto
d’Adda di Fagagna, Fabrizio http://orcid.org/0000-0002-9603-5966
Funding for this research was provided by:
AIRC 5x1000
Article History
Received: 5 January 2023
Revised: 19 January 2023
Accepted: 1 February 2023
First Online: 9 February 2023
Competing interests
: Alberto Bardelli (ABa) served in a consulting/advisory role for Illumina, and Inivata and Guardant Health. ABa is a member of the scientific advisory board of Neophore, Inivata and Roche Genentech CRC Advisory Board. ABa receipts grants/research supports from Neophore, Astrazeneca and Boehringer. ABa is cofounder and shareholder of NeoPhore limited. Livio Trusolino (LT) has received research grants from Menarini, Merck KGaA, Merus, Pfizer, Servier and Symphogen. Sabrina Arena (SA) acted as consultant for MSD Italia outside the submitted work and has a patent 102022000007535 pending. The rest of the authors declared no competing interests.
: PDOs were obtained from patients treated by liver metastasectomy at the Candiolo Cancer Institute (Candiolo, Torino, Italy), Mauriziano Umberto (Torino), and San Giovanni Battista (Torino). All patients provided informed consent. Samples were procured, and the study was conducted under the approval of the Review Boards of the Institutions. HROC cell lines were kindly provided by Dr. Michael Linnebacher from University of Rostock.